Literature DB >> 21263050

In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.

Alex van Belkum1, Ahmed H Fahal, Wendy W J van de Sande.   

Abstract

Presently, therapy of eumycetoma in Sudan is still based on surgery combined with prolonged ketoconazole therapy. This usually results in a poor clinical outcome. To determine if posaconazole and terbinafine could offer better therapeutic alternatives, the in vitro susceptibilities of 34 Madurella mycetomatis strains were determined. It appeared that posaconazole was highly active against M. mycetomatis but terbinafine was only moderately active. Since posaconazole has an excellent safety profile, it might provide an important alternative in mycetoma therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21263050      PMCID： PMC3067195          DOI： 10.1128/AAC.01045-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

Authors:  Fèlix Gilgado; Carolina Serena; Josep Cano; Josepa Gené; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

2.  Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.

Authors:  Wendy W J van de Sande; Ad Luijendijk; Abdalla O A Ahmed; Irma A J M Bakker-Woudenberg; Alex van Belkum
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size.

Authors:  Wendy W J van de Sande; Roy Gorkink; Guus Simons; Alewijn Ott; Abdalla O A Ahmed; Henri Verbrugh; Alex van Belkum
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  An evaluation of the in vitro activity of terbinafine.

Authors:  C J Jessup; N S Ryder; M A Ghannoum
Journal:  Med Mycol       Date:  2000-04       Impact factor: 4.076

5.  Clinical efficacy and safety of oral terbinafine in fungal mycetoma.

Authors:  Bassirou N'diaye; Mame T Dieng; Antonio Perez; Marlies Stockmeyer; Rajesh Bakshi
Journal:  Int J Dermatol       Date:  2006-02       Impact factor: 2.736

6.  Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for identification of Madurella mycetomatis.

Authors:  A O Ahmed; M M Mukhtar; M Kools-Sijmons; A H Fahal; S de Hoog; B G van den Ende; E E Zijlstra; H Verbrugh; E S Abugroun; A M Elhassan; A van Belkum
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species.

Authors:  H Badali; M J Najafzadeh; M van Esbroeck; E van den Enden; B Tarazooie; J F G M Meis; G S de Hoog
Journal:  Med Mycol       Date:  2010-03       Impact factor: 4.076

8.  Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites.

Authors:  J M Kovarik; E A Mueller; H Zehender; J Denouël; H Caplain; L Millerioux
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.

Authors:  Ricardo Negroni; Angela Tobón; Beatriz Bustamante; Maria Aparecida Shikanai-Yasuda; Hernando Patino; Angela Restrepo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2005 Nov-Dec       Impact factor: 1.846

10.  In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.

Authors:  Abdalla O A Ahmed; Wendy W J van de Sande; Wim van Vianen; Alex van Belkum; Ahmed H Fahal; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
View more
  18 in total

1.  Pyomelanin Secretion in Madurella mycetomatis Interferes with Spectrophotometric Endpoint Reading Using the Sensititre YeastOne alamarBlue Assay but Not with Visual Endpoint Reading.

Authors:  B Nyuykonge; P D Croughs; A H Fahal; A Verbon; W W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.

Authors:  Sarah Abdalla Ahmed; Wendy Kloezen; Ahmed H Fahal; G Sybren de Hoog; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

3.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

4.  In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Authors:  Wendy Kloezen; Jacques F Meis; Ilse Curfs-Breuker; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

5.  Eumycetoma by Madurella mycetomatis with 30 years of evolution: therapeutic challenge.

Authors:  Felipe Maurício Soeiro Sampaio; Maria Clara Gutierrez Galhardo; Leonardo Pereira Quintella; Paulo Roberto Cotrim de Souza; Janice Mary Chicarino de Oliveira Coelho; Antonio Carlos Francesconi do Valle
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

6.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184

Review 7.  The mycetoma knowledge gap: identification of research priorities.

Authors:  Wendy W J van de Sande; El Sheikh Maghoub; Ahmed H Fahal; Michael Goodfellow; Oliverio Welsh; Ed Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

8.  Madurella mycetomatis is highly susceptible to ravuconazole.

Authors:  Sarah Abdalla Ahmed; Wendy Kloezen; Frederick Duncanson; Ed E Zijlstra; G Sybren de Hoog; Ahmed H Fahal; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19

9.  The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection.

Authors:  Najwa A Mhmoud; Ahmed Hassan Fahal; El Sheikh Mahgoub; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19

10.  The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent.

Authors:  Hassabelrasoul Elfadil; Ahmed Fahal; Wendy Kloezen; Elhadi M Ahmed; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.